En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
INNOSUISSE
Numéro de projet
13939.1;8 PFLS-LS
Titre du projet
Generation of a genetically characterized and improved CHO cell-based GMP production platform
Titre du projet anglais
Generation of a genetically characterized and improved CHO cell-based GMP production platform

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Description succincte
-
Anzeigen
-
Anzeigen
Résumé des résultats (Abstract)
-
Anzeigen
-
Anzeigen

Textes saisis


CatégorieTexte
Description succincte
(Anglais)
Generation of a genetically characterized and improved CHO cell-based GMP production platform
Description succincte
(Français)
Generation of a genetically characterized and improved CHO cell-based GMP production platform
Résumé des résultats (Abstract)
(Anglais)
We propose to devise a CHO cell-based platform with a fully sequenced annotated genome, and to engineer it to facilitate the identification of new protein therapeutics, to decrease production costs and to improve the quality and safety of therapeutic proteins. Our scientific aims are: i) to complete the sequencing and annotate the CHO cell genome, ii) to develop a more efficient gene transfer process for improved therapeutic protein expression based on the genome sequence, and iii) to establish a process to characterize the genome of therapeutic-producing CHO cell clones, to provide better characterized therapeutic proteins and to facilitate regulatory approval.
Résumé des résultats (Abstract)
(Français)
We propose to devise a CHO cell-based platform with a fully sequenced annotated genome, and to engineer it to facilitate the identification of new protein therapeutics, to decrease production costs and to improve the quality and safety of therapeutic proteins. Our scientific aims are: i) to complete the sequencing and annotate the CHO cell genome, ii) to develop a more efficient gene transfer process for improved therapeutic protein expression based on the genome sequence, and iii) to establish a process to characterize the genome of therapeutic-producing CHO cell clones, to provide better characterized therapeutic proteins and to facilitate regulatory approval.